SNMMI, other advocacy groups and radiopharmaceutical vendors have urged the CMS to categorize diagnostic radiotracers as drugs, rather than as supplies, and legislation to do so may be introduced soon in Congress. Current radiotracer reimbursement under ambulatory payment classifications in the Medicare Hospital Outpatient Prospective Payment System is inadequate to address the cost of some tracers and may deter the use of newer tracers, as well as discourage research and development investment, the groups said.
SNMMI, others call for CMS reclassification of radiotracers
Sign up for SNMMI SmartBrief
Nuclear medicine and molecular imaging news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.